Encube Ethicals announces new high potency topical manufacturing suite

Company's $4 million investment reflects market need for contract service providers who can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.

The new 350-m2 facility, at its site in Goa, follows a $4 million investment by the company last year to bolster its topical manufacturing capabilities. It has an in-house isolator technology that caters for topical products, which include highly potent active pharmaceutical ingredients (HPAPIs), such as pesticides, immunosuppressants and skin oncology drugs.

The facility, which was built in response to customer and market demand for Encube’s services, adds an additional manufacturing line to the company’s portfolio, taking the total number of SKUs manufactured at the site to over 400.

Mehul Shah, managing director at Encube Ethicals, who founded the business in 1998, said: “There is a real gap in the market for contract service providers that can provide innovative and cost-effective topical manufacturing capabilities for products that include highly potent actives.

“As a result, we have experienced high demand for these services and chose to invest in a new facility to increase our capacity. Now that we’re fully operational, we can continue to cater for new small pharma, biotech and virtual customers, as well as continue to support our current multi-national customers who are entering the high potency topical space.”

Based in Mumbai and Goa, the company has over 20 years’ experience of providing an end-to-end, high-quality service for topical products.

The team at the new facility are experienced in handling a number of immunosuppressant topicals including, Tacrolimus and Primecrolimus, as well as skin oncology products such as Fluorouracil. High potency manufacturing is carried out using sophisticated material handling equipment to ensure safety of the operators and the product.